#VisualAbstract: Effectiveness of lorlatinib in advanced anaplastic lymphoma kinase-positive lung cancer
1. In this randomized, double-blind, phase three trial, progression-free survival was higher in patients treated with lorlatinib compared with crizotinib. ...